Literature DB >> 15105167

Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men.

Jean-Pierre Gutzwiller1, Lukas Degen, Daniel Matzinger, Sven Prestin, Christoph Beglinger.   

Abstract

Glucagon-like peptide-1 (GLP-1) and CCK-33 were intravenously infused alone or in combination into normal weight men for 60 min before they were served a lunch of ham sandwiches, chocolate mousse, and orange juice. Infusion of GLP-1 (dose: 0.9 pmol x kg(-1) x min(-1)) or CCK-33 (dose: 0.2 pmol x kg(-1) x min(-1)) each reduced calorie intake of the test meal. However, simultaneous infusion of these peptide doses reduced calorie intake less than the sum of the peptides' individual effects. Infusions of the same doses of GLP-1 plus CCK-33 had neither individual nor interactive effects on meal size or calorie consumption. The combination of GLP-1 plus CCK-33 induced, however, a significant reduction in hunger feelings in the premeal period (P = 0.036 vs. all other treatments). In summary, intravenous infusion of near physiological doses of CCK-33 and GLP-1 produced specific inhibitions of hunger feeling in men; the simultaneous infusion resulted in an infra-additive reduction in calorie consumption, rejecting thereby the hypothesis that the two peptides exert a positive synergistic effect on food intake compared with the effects observed with infusion of individual peptides. In conclusion, CCK and GLP-1 are meal-related satiety signals that are released from the gastrointestinal tract during food intake.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105167     DOI: 10.1152/ajpregu.00599.2003

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  21 in total

Review 1.  Intestinal GLP-1 and satiation: from man to rodents and back.

Authors:  R E Steinert; C Beglinger; W Langhans
Journal:  Int J Obes (Lond)       Date:  2015-08-28       Impact factor: 5.095

Review 2.  Central control of body weight and appetite.

Authors:  Stephen C Woods; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

Review 3.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 4.  New advances in models and strategies for developing anti-obesity drugs.

Authors:  Gilbert W Kim; Jieru E Lin; Erik S Blomain; Scott A Waldman
Journal:  Expert Opin Drug Discov       Date:  2013-04-29       Impact factor: 6.098

Review 5.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 6.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 7.  Pharmacological management of appetite expression in obesity.

Authors:  Jason C G Halford; Emma J Boyland; John E Blundell; Tim C Kirkham; Joanne A Harrold
Journal:  Nat Rev Endocrinol       Date:  2010-03-16       Impact factor: 43.330

Review 8.  Interaction between gastric and upper small intestinal hormones in the regulation of hunger and satiety: ghrelin and cholecystokinin take the central stage.

Authors:  Andreas Stengel; Yvette Taché
Journal:  Curr Protein Pept Sci       Date:  2011-06       Impact factor: 3.272

9.  PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.

Authors:  Benjamin C T Field; Alison M Wren; Veronique Peters; Kevin C R Baynes; Niamh M Martin; Michael Patterson; Sara Alsaraf; Vian Amber; Katie Wynne; Mohammad A Ghatei; Stephen R Bloom
Journal:  Diabetes       Date:  2010-03-31       Impact factor: 9.461

10.  New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

Authors:  Baptist Gallwitz
Journal:  Rev Diabet Stud       Date:  2005-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.